Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.34 |
| ▸ | NPY1R | P25929 | 2/20 | 0.34 |
| ▸ | NPY4R | P50391 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30855386 | 1.00 | PTGS1 (0.37) | PTGS1PTGS2KMT2ANPY5RNPY1R | |
| SCHEMBL25786259 | 0.99 | PTGS1 (0.37) | PTGS1PTGS2KMT2ANPY5RNPY1R | |
| SCHEMBL30855381 | 0.92 | PTGS1 (0.36) | PTGS1PTGS2KMT2ANPY5RNPY1R | |
| SCHEMBL19019929 | 0.90 | PTGS1 (0.37) | PTGS1PTGS2KMT2ANPY5RNPY1R | |
| SCHEMBL19375644 | 0.90 | MMP3 (0.35) | PTGS1PTGS2KMT2ANPY5RNPY1R | |
| SCHEMBL17823173 | 0.90 | PTGS1 (0.40) | PTGS1PTGS2KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL17823174 | 0.90 | PTGS1 (0.40) | PTGS1PTGS2KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL31014151 | 0.90 | KMT2A (0.39) | PTGS1PTGS2KMT2ANPY5RNPY1R | |
| SCHEMBL28504965 | 0.89 | PTGS1 (0.38) | PTGS1PTGS2KMT2AHRH1ALDH1A1 | |
| SCHEMBL22459909 | 0.89 | MMP3 (0.35) | PTGS1PTGS2KMT2ANPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024153127-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-10682371-B2 | Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-10682371-B2 | Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-3184540-A1 | SPECIFICALLY ACTIVATED MICROMOLECULAR TARGET COUPLING BODY IN TUMOR MICROENVIRONMENT AND USE THEREOF | Yafei Shanghai Biolog Medicine Science& Technology (CN) | 2017-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | PTGS1 4665/4885PTGS2 4693/4885KMT2A 1974/4885 |
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | CD4, MET, TNFSF10 | PTGS1 2315/4885PTGS2 2220/4885KMT2A 555/4885 |
| US-10682371-B2 | Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof | MET, ARG1, CD4 | PTGS1 1498/4885PTGS2 1531/4885KMT2A 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.